119 related articles for article (PubMed ID: 35812817)
1. Rationale and design of a multicenter, single-group, open-label trial aiming at investigating the effectiveness of elobixibat for loss of defecation desire in patients with chronic constipation.
Yamamoto A; Kessoku T; Tanaka K; Takahashi K; Kasai Y; Ozaki A; Iwaki M; Kobayashi T; Yoshihara T; Misawa N; Ohkuma K; Fuyuki A; Higurashi T; Hosono K; Yoneda M; Iwasaki T; Kurihashi T; Nakatogawa M; Suzuki A; Taguri M; Oyamada S; Ariyoshi K; Kobayashi N; Ichikawa Y; Nakajima A
Contemp Clin Trials Commun; 2022 Aug; 28():100958. PubMed ID: 35812817
[TBL] [Abstract][Full Text] [Related]
2. Rationale and design of a multicentre, 12-week, randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated trial to investigate the efficacy and safety of elobixibat for chronic constipation.
Tanaka K; Kessoku T; Yamamoto A; Takahashi K; Kasai Y; Ozaki A; Iwaki M; Kobayashi T; Yoshihara T; Misawa N; Kato T; Arimoto J; Fuyuki A; Sakai E; Higurashi T; Chiba H; Hosono K; Yoneda M; Iwasaki T; Kurihashi T; Nakatogawa M; Suzuki A; Taguri M; Oyamada S; Ariyoshi K; Kobayashi N; Ichikawa Y; Nakajima A
BMJ Open; 2022 May; 12(5):e060704. PubMed ID: 35636802
[TBL] [Abstract][Full Text] [Related]
3. Rationale and design of a randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated phase 2a study to investigate the efficacy and safety of elobixibat in combination with cholestyramine for non-alcoholic fatty liver disease.
Kessoku T; Kobayashi T; Ozaki A; Iwaki M; Honda Y; Ogawa Y; Imajo K; Saigusa Y; Yamamoto K; Yamanaka T; Usuda H; Wada K; Yoneda M; Saito S; Nakajima A
BMJ Open; 2020 Sep; 10(9):e037961. PubMed ID: 32907904
[TBL] [Abstract][Full Text] [Related]
4. Investigating the efficacy and safety of elobixibat, an ileal bile acid transporter inhibitor, in patients with Parkinson's disease with chronic constipation: a multicentre, placebo-controlled, randomised, double-blind, parallel-group stud (CONST-PD).
Hatano T; Oyama G; Shimo Y; Ogaki K; Nishikawa N; Fukae J; Nakamura R; Kurita N; Tsunemi T; Oji Y; Saiki S; Nishioka K; Takeshige-Amano H; Taniguchi D; Ogawa T; Kamo H; Eguchi H; Fuse A; Nakajima A; Kano M; Nakajima S; Yanagisawa N; Hattori N
BMJ Open; 2022 Feb; 12(2):e054129. PubMed ID: 35149566
[TBL] [Abstract][Full Text] [Related]
5. Determining an optimal clinical dose of elobixibat, a novel inhibitor of the ileal bile acid transporter, in Japanese patients with chronic constipation: a phase II, multicenter, double-blind, placebo-controlled randomized clinical trial.
Nakajima A; Seki M; Taniguchi S
J Gastroenterol; 2018 Apr; 53(4):525-534. PubMed ID: 28840422
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial.
Nakajima A; Seki M; Taniguchi S; Ohta A; Gillberg PG; Mattsson JP; Camilleri M
Lancet Gastroenterol Hepatol; 2018 Aug; 3(8):537-547. PubMed ID: 29805116
[TBL] [Abstract][Full Text] [Related]
7. Elobixibat, an ileal bile acid transporter inhibitor, induces giant migrating contractions during natural defecation in conscious dogs.
Taniguchi S; Yano T; Imaizumi M; Manabe N
Neurogastroenterol Motil; 2018 Dec; 30(12):e13448. PubMed ID: 30129138
[TBL] [Abstract][Full Text] [Related]
8. Elobixibat improves rectal sensation in patients with chronic constipation aged ≥60 years: a randomised placebo-controlled study.
Manabe N; Umeyama M; Ishizaki S; Ota T; Kuratani S; Katsumata R; Fujita M; Haruma K; Camilleri M
BMJ Open Gastroenterol; 2023 Nov; 10(1):. PubMed ID: 37993269
[TBL] [Abstract][Full Text] [Related]
9. Difference in Defecation Desire Between Patients With and Without Chronic Constipation: A Large-Scale Internet Survey.
Ohkubo H; Takatsu T; Yoshihara T; Misawa N; Ashikari K; Fuyuki A; Matsuura T; Higurashi T; Yamamoto K; Matsumoto H; Odaka T; Lembo AJ; Nakajima A
Clin Transl Gastroenterol; 2020 Sep; 11(9):e00230. PubMed ID: 32858571
[TBL] [Abstract][Full Text] [Related]
10. The benefit of elobixibat in chronic constipation is associated with faecal deoxycholic acid but not effects of altered microbiota.
Misawa N; Higurashi T; Takatsu T; Iwaki M; Kobayashi T; Yoshihara T; Ashikari K; Kessoku T; Fuyuki A; Matsuura T; Ohkubo H; Usuda H; Wada K; Naritaka N; Takei H; Nittono H; Matsumoto M; Honda A; Nakajima A; Camilleri M
Aliment Pharmacol Ther; 2020 Sep; 52(5):821-828. PubMed ID: 32687674
[TBL] [Abstract][Full Text] [Related]
11. Effect of single and multiple doses of elobixibat, an ileal bile acid transporter inhibitor, on chronic constipation: A randomized controlled trial.
Kumagai Y; Amano H; Sasaki Y; Nakagawa C; Maeda M; Oikawa I; Furuie H
Br J Clin Pharmacol; 2018 Oct; 84(10):2393-2404. PubMed ID: 29959787
[TBL] [Abstract][Full Text] [Related]
12. Elobixibat for the treatment of constipation.
Chedid V; Vijayvargiya P; Camilleri M
Expert Rev Gastroenterol Hepatol; 2018 Oct; 12(10):951-960. PubMed ID: 30204504
[TBL] [Abstract][Full Text] [Related]
13. Uncontrolled, Open-Label Pre-Dinner Administration of Elobixibat in Japanese Adults with Chronic Constipation: A Retrospective Chart Review.
Odaka T; Tominaga K
Curr Ther Res Clin Exp; 2020; 93():100616. PubMed ID: 33320111
[TBL] [Abstract][Full Text] [Related]
14. Elobixibat alleviates chronic constipation in hemodialysis patients: a questionnaire-based study.
Kamei D; Kamei Y; Nagano M; Mineshima M; Nitta K; Tsuchiya K
BMC Gastroenterol; 2020 Jan; 20(1):26. PubMed ID: 32005162
[TBL] [Abstract][Full Text] [Related]
15. [Pharmacological characteristics and clinical study results of ileal bile acid transporter inhibitor elobixibat (GOOFICE
Ikeda N; Taniguchi S; Seki M
Nihon Yakurigaku Zasshi; 2019; 153(3):129-138. PubMed ID: 30867382
[TBL] [Abstract][Full Text] [Related]
16. Impact of elobixibat on serum and fecal bile acid levels and constipation symptoms in patients with chronic constipation.
Nakajima A; Ishizaki S; Matsuda K; Kurosu S; Taniguchi S; Gillberg PG; Mattsson JP; Hasunuma T; Camilleri M
J Gastroenterol Hepatol; 2022 May; 37(5):883-890. PubMed ID: 35168298
[TBL] [Abstract][Full Text] [Related]
17. Specific inhibition of bile acid transport alters plasma lipids and GLP-1.
Rudling M; Camilleri M; Graffner H; Holst JJ; Rikner L
BMC Cardiovasc Disord; 2015 Jul; 15():75. PubMed ID: 26197999
[TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of Elobixibat, an Ileal Bile Acid Transporter Inhibitor, in Elderly Patients With Chronic Idiopathic Constipation According to Administration Time: Interim Analysis of Post-marketing Surveillance.
Nakajima A; Fujimaki M; Arai Y; Emori K
J Neurogastroenterol Motil; 2022 Jul; 28(3):431-441. PubMed ID: 35799237
[TBL] [Abstract][Full Text] [Related]
19. Open-Label, Single-Center, Single-Arm Study Evaluating the Efficacy and Safety of Elobixibat for Chronic Constipation in Patients With Heart Failure.
Fujisue K; Ito M; Matsuzawa Y; Arima Y; Takashio S; Sueta D; Araki S; Hanatani S; Yamanaga K; Yamamoto M; Kaneko S; Yamamoto E; Matsushita K; Soejima H; Tsujita K
Circ Rep; 2024 Mar; 6(3):55-63. PubMed ID: 38464992
[No Abstract] [Full Text] [Related]
20. Effect of dexamethasone in patients with ARDS and COVID-19 - prospective, multi-centre, open-label, parallel-group, randomised controlled trial (REMED trial): A structured summary of a study protocol for a randomised controlled trial.
Maláska J; Stašek J; Duška F; Balík M; Máca J; Hruda J; Vymazal T; Klementová O; Zatloukal J; Gabrhelík T; Novotný P; Demlová R; Kubátová J; Vinklerová J; Svobodník A; Kratochvíl M; Klučka J; Gál R; Singer M;
Trials; 2021 Mar; 22(1):172. PubMed ID: 33648568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]